People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eliem Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $253.2M | $1.3B | 2021 |
| Rivus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $223.5M | $416.3M | 2025 |
| Aviceda Therapeutics, Inc. | — | Biotechnology | Series D+ | $173.6M | $707.0M | 2024 |
Erin Lavelle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Erin Lavelle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Patrick Enright | 1 | 10 |
| David Guyer | 1 | 8 |
| Derek DiRocco | 1 | 7 |
| Adam Rosenberg | 1 | 6 |
| Robert Kniaz | 1 | 5 |
| Stephen Thomas | 1 | 5 |
| Francesco De Rubertis | 1 | 4 |
| Ian Smith | 1 | 4 |
| Patrick Johnson | 1 | 4 |
| Liam Ratcliffe | 1 | 4 |
| Julio Vega | 1 | 3 |
| Michael Tolentino | 1 | 3 |
| Kyrylo Bigay | 1 | 2 |
| Mariusz Gralewski | 1 | 2 |
| Dmytro Voloshyn | 1 | 2 |
| Jayson Dallas | 1 | 2 |
| Robert Azelby | 1 | 2 |
| Ross Darwin | 1 | 2 |
| Aoife Brennan | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.